Genotoxicity evaluation of graphene derivatives by a battery of in vitro assays

Cebadero-Domínguez, Óscar; Medrano-Padial, Concepción; Puerto, María; Sánchez-Ballester, Soraya; Cameán, Ana M.; Jos, Ángeles

doi:10.1016/j.cbi.2023.110367

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Lingaraju et al [ 35 ] observed a concentration-dependent cytotoxicity leading to a median inhibitory concentration (IC50-24 h) of 357.53 µg/mL, and Zuchowska et al [ 37 ] observed cytotoxicity at all tested concentrations (200–800 µg/mL), although they were higher than in the present work. The different cytotoxicity effects observed could be due to its physicochemical properties, such as size, shape, aggregation state, and its interactions with cells [ 38 ]. However, there are no previous studies on the effects of digested rGO or any other digested GRM in this cell model [ 39 ].…”

Section: Resultsmentioning

confidence: 99%

Impact of Gastrointestinal Digestion In Vitro Procedure on the Characterization and Cytotoxicity of Reduced Graphene Oxide

et al. 2023

Self Cite

View full text Add to dashboard Cite

The growing interest in graphene derivatives is a result of their variety of applications in many fields. Due to their use, the oral route could be a potential way of entrance for the general population. This work assesses the biotransformation of reduced graphene oxide (rGO) after an in vitro digestion procedure (mouth, gastric, intestinal, and colon digestion), and its toxic effects in different cell models (HepG2, Caco-2, and 3D intestinal model). The characterization of rGO digestas evidenced the agglomeration of samples during the in vitro gastrointestinal (g.i.) digestion. Internalization of rGO was only evident in Caco-2 cells exposed to the colonic phase and no cellular defects were observed. Digestas of rGO did not produce remarkable cytotoxicity in any of the experimental models employed at the tested concentrations (up to 200 µg/mL), neither an inflammatory response. Undigested rGO has shown cytotoxic effects in Caco-2 cells, therefore these results suggest that the digestion process could prevent the systemic toxic effects of rGO. However, additional studies are necessary to clarify the interaction of rGO with the g.i. tract and its biocompatibility profile.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of Gastrointestinal Digestion In Vitro Procedure on the Characterization and Cytotoxicity of Reduced Graphene Oxide

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…[38] Although rGO has the potential to impact biological systems positively, several studies have also shown their detrimental impact on cell survival. [86] To confirm that the GNP-SP hydrogel and rGO-SP hybrid hydrogel preserve the excellent biocompatibility features of SP, they were assessed on cells involved in skin wound healing (NIH-3T3 and HUVEC cells) and bone tissue regeneration (MC3T3 cells).…”

Section: Cytocompatibility and Cell Migrationmentioning

confidence: 99%

Teicoplanin‐Decorated Reduced Graphene Oxide Incorporated Silk Protein Hybrid Hydrogel for Accelerating Infectious Diabetic Wound Healing and Preventing Diabetic Foot Osteomyelitis

Bakadia,

Zheng,

Qaed Ahmed

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Developing hybrid hydrogel dressings with anti‐inflammatory, antioxidant, angiogenetic, and antibiofilm activities with higher bone tissue penetrability to accelerate diabetic wound healing and prevent diabetic foot osteomyelitis (DFO) is highly desirable in managing diabetic wounds. Herein, the glycopeptide teicoplanin is used for the first time as a green reductant to chemically reduce graphene oxide (GO). The resulting teicoplanin‐decorated reduced graphene oxide (rGO) is incorporated into a mixture of silk proteins (SP) and crosslinked with genipin to yield a physicochemically crosslinked rGO‐SP hybrid hydrogel. This hybrid hydrogel exhibits high porosity, self‐healing, shear‐induced thinning, increased cell proliferation and migration, and mechanical properties suitable for tissue engineering. Moreover, the hybrid hydrogel eradicates bacterial biofilms with a high penetrability index in agar and hydroxyapatite discs covered with biofilms, mimicking bone tissue. In vivo, the hybrid hydrogel accelerates the healing of non‐infected wounds in a diabetic rat and infected wounds in a diabetic mouse by up‐regulating anti‐inflammatory cytokines and down‐regulating matrix metalloproteinase‐9, promoting M2 macrophage polarization and angiogenesis. The implantation of hybrid hydrogel into the infected site of mouse tibia improves bone regeneration. Hence, the rGO‐SP hybrid hydrogel can be a promising wound dressing for treating infectious diabetic wounds, providing a further advantage in preventing DFO.This article is protected by copyright. All rights reserved

show abstract

In vitro safety assessment of reduced graphene oxide in human monocytes and T cells.

Cebadero-Domínguez

Casas-Rodríguez

Puerto

et al. 2023

Environmental Research

View full text Add to dashboard Cite

Genotoxicity evaluation of graphene derivatives by a battery of in vitro assays

Cited by 4 publications

References 37 publications

Impact of Gastrointestinal Digestion In Vitro Procedure on the Characterization and Cytotoxicity of Reduced Graphene Oxide

Impact of Gastrointestinal Digestion In Vitro Procedure on the Characterization and Cytotoxicity of Reduced Graphene Oxide

Teicoplanin‐Decorated Reduced Graphene Oxide Incorporated Silk Protein Hybrid Hydrogel for Accelerating Infectious Diabetic Wound Healing and Preventing Diabetic Foot Osteomyelitis

In vitro safety assessment of reduced graphene oxide in human monocytes and T cells.

Contact Info

Product

Resources

About